LOL

Quick Take – You were all warned about Puma. – (PBYI)

In what should come as no surprise to anyone with a clue, Neratinib aka Nerlynx, from former bucket shop biotech analyst Alan Auerbach‘s Puma Biotechnology (PBYI) has been a complete failure in the marketplace. In September 2016 readers were all warned this would be the case. As our friend @b4uconsent pointed out almost 3 years ago:

It’s a snore of a TKI (PD-1/PD-L1s are becoming old news, and investors are supposed to get amped about a TKI?) that perpetuates fear mongering to patients who don’t understand recurrence risk, it de-prioritizes QOL, and it indulges a wasteful healthcare system where anything other than gross inferiority must equate clinical benefit. But who’s going to prescribe this? Who’s going to take it?

and

there is a risk of “life-threatening” side effects when, per the 92% DFS rate at two years, the cancer itself is not life-threatening

and

Neratinib is a drug no one needs or asked for

Alan, and mentor Lindsay R, merely got lucky with Cougar, nothing more. In this instance, prophecy did not fail. Puma did.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR. 
Advertisements

Quick Take – What’s in a name? (THCT)

Presenting just one aspect from the curious case of Vegas based, pink sheet stinker, THC Therapeutics (THCT), or is it Millenium Blockchain, or is it Millenial Weedscam? No matter what, it was, is and always will be a fairytale. As of today, the 5th of April 2019, a $220mm vape dream.

THCTNameChanges

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

The Map and the Territory: Who Controls Gopher Protocol? – GOPH

As part of our continuing series on filthy reverse merger Gopher Protocol (GOPH), we’ll start to explore exactly who controls the company.

Just looking at common stock is not enough, one must look at the various series of convertible bonds, warrants, and preferred stock. Some of which have conversion prices under 1c!

Here is a snapshot of GOPH ownership from before the stock promotion began in earnest. These numbers have certainly changed.

The short answer, is Galina Vaynter, through various entities and related parties. These include companies headed by her husband, Avady aka Vadim Vaynter, her daughter Regina Kats, and various straw men and women, including this guy, Kenneth Jeremy Smith, in Spokane, WA.

KJSmithEDIT

Together, these account for at least 85% control of GOPH (and possibly more) before the promotion started in earnest. See here:

WhoControlsGOPH-map

There’s lots more to come….

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

Script Data, Part 4 – A Tale of Two Drugs, Continued. – MNKD, SNY

An update in our ongoing examination of the performance of two recent drug launches from Sanofi (SNY). One is Toujeo, an injectable. The other is Mannkind‘s (MNKD) much hyped, beloved by retail investors, inhaled insulin Afrezza. These two drugs are both for the treatment of diabetes. Sanofi uses the same salesforce, who would be detailing the exact same doctors for both drugs. Can you spot the commercial flop? Remember folks, we are looking for “up and to the right”, we don’t want to see the patient flatlining.

Spot the dismal, pathetic, failure.

Spot the dismal, pathetic, failure.

Can Jefferies’ resident Mannkind moron Shaunak Deepak? Just for fun we’ve extended out the Afrezza data for the full 23 weeks it has been on the market. Toujeo has only been on the market for four months as of the last sales update.

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

Quick Take – Bye Bye Mark Ahn (GALE)

As tweeted last night by The Street.com’s Adam Feuerstein, the smug Mark Ahn is out at dreadful Galena Biopharmaceutical (GALE). Read more here.

The sell-side analysts whoring themselves out for banking business, like Needham’s moronic Chad Messer (read about him here and here) will now have to dust off the pads and kneel before newly promoted GALE CEO Mark Schwartz.

For those playing at home, the case to watch (or better yet send in an FOIA request) is:

In the Matter of Galena Biopharma, SEC File No. HO 12356 now known as  “In the Matter of Certain Stock Promotions”

No wonder the GALE-eediots have been so silent recently.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Galena and the Epsilon Sock Puppets – GALE

A number of comments have recently been submitted for approval to the recent posts on bio-dreck Galena Biopharma (GALE), by commenters “Don Petty” and “Bryce in TX“. [Similar comments have been posted to other articles on other site, like Seeking Alpha, by Don and Bryce as well.]

Both seem to be stubbornly stupid GALE bulls.

It turns out that all 6 comments are from the exact same email address and posted from the same ip address. Nice try.

(more…)

Quick Take – The Uri Landesman Magical Mystery Tour (ECTE, NEOP)

Our good friend, and Mark Nordlicht‘s right hand man, Uri Landesman was back on the air this holiday-shortened week, discussing everyone’s favorite tired old bio-dreck, reverse merger company Echo Therapeutics (ECTE) and bucket shop IPO Neoprobe (NEOP). Read more about ECTE here, and a great piece on NEOP, by Martin Shkreli, here. And check out Uri’s performance!

Happy Holidays!

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.